Boufassa F, Carré N, Deveau C, Sultan Y, Gazengel C, Blanc A, Peynet J, Ramirez D, Meyer L
Unité INSERM U-292, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
Hematol Cell Ther. 1996 Apr;38(2):193-8. doi: 10.1007/s00282-996-0193-7.
HEMOCO is a multicenter prospective cohort set up in 1989 to monitor 407 French hemophiliacs infected by HIV-1 and recruited in 4 hemophilia treatment centers in the Paris region. As of 15 July 1995, 42% of the patients in the cohort had developed stage B HIV disease and 29% stage C disease (AIDS); 23.1% of the patients had died. The cumulative proportion of patients with AIDS was 4.5% at 5 years and 27.4% at 10 years, while the respective mortality rates were 3.8% and 19.5%. In our study, only age was predictive of AIDS, with an estimated relative risk of 1.2 per 10-year age increment; this factor was also predictive of death. After 10 years of follow-up, 6.1% of the study population had no clinical or laboratory signs of immunodepression. The follow-up protocol in the HEMOCO protocol is the same as that in the French SEROCO study, which includes men infected by HIV-1 through sexual contact. This will allow us to compare the progression of HIV infection between these two exposure groups.
HEMOCO是1989年设立的一个多中心前瞻性队列研究，旨在监测407名感染HIV-1的法国血友病患者，这些患者是在巴黎地区的4个血友病治疗中心招募的。截至1995年7月15日，队列中的42%的患者已发展为B期HIV疾病，29%为C期疾病（艾滋病）；23.1%的患者已经死亡。艾滋病患者的累积比例在5年时为4.5%，在10年时为27.4%，而相应的死亡率分别为3.8%和19.5%。在我们的研究中，只有年龄可预测艾滋病，估计每增加10岁相对风险为1.2；该因素也可预测死亡。经过10年的随访，6.1%的研究人群没有免疫抑制的临床或实验室迹象。HEMOCO方案中的随访方案与法国SEROCO研究相同，后者包括通过性接触感染HIV-1的男性。这将使我们能够比较这两个暴露组之间HIV感染的进展情况。
